Evidence map›Paper›PMID 34638347›Full record

ArticleCancers2021

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.

Simone Claudiani, Clinton C Mason, Dragana Milojkovic, Andrea Bianchi, Cristina Pellegrini, Antinisca Di Marco, Carme R Fiol, Mark Robinson, Kanagaraju Ponnusamy, Katya Mokretar and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Simone ClaudianiCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Clinton C MasonDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University of Utah, Salt Lake City, UT 84108, USA.ORCID 0000-0002-9566-4568
Dragana MilojkovicCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Andrea BianchiDepartment of Information Engineering, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0002-6046-4355
Cristina PellegriniDepartment of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy.
Antinisca Di MarcoDepartment of Information Engineering, University of L'Aquila, 67100 L'Aquila, Italy.
Carme R FiolCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Mark RobinsonCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Kanagaraju PonnusamyCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Katya MokretarCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Avirup ChowdhuryCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.ORCID 0000-0001-9817-0603
Michael AlbertCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Alistair G ReidMolecular Pathology Unit, Liverpool University, Liverpool L7 8XP, UK.
Michael W DeiningerVersiti Blood Research Institute, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Kikkeri NareshCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Jane F ApperleyCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Jamshid S KhorashadCentre for Haematology, Department of Immunology and Inflammation, Imperial College, London W12 0NN, UK.
Imperial College London · GBUniversity of L'Aquila · ITMedical College of Wisconsin · USUniversity of Liverpool · GBUniversity of Utah · US

Funding

Kay Kendall Leukaemia Fund KKL1072
6 · The paper itself

Abstract

As the first FDA-approved tyrosine kinase inhibitor for treatment of patients with myelofibrosis (MF), ruxolitinib improves clinical symptoms but does not lead to eradication of the disease or significant reduction of the mutated allele burden. The resistance of MF clones against the suppressive action of ruxolitinib may be due to intrinsic or extrinsic mechanisms leading to activity of additional pro-survival genes or signalling pathways that function independently of JAK2/STAT5. To identify alternative therapeutic targets, we applied a pooled-shRNA library targeting ~5000 genes to a

Indexed as

carfilzomibmyelofibrosisruxolitinibshRNA library screen

Identifiers

PMID34638347
PMCPMC8507927
OpenAlexW3202635807

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.